We read with interest the article by Sumi I et al. i [1] about the pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model (HFIM) against I Klebsiella pneumoniae i . Optimization and evaluation of piperacillin-tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling. Of note, while f I T i SB >MIC sb were above 100% for almost all regimens/MIC pairings, only 12/1.5 g piperacillin/tazobactam continuous infusion against the Kp69 isolate (piperacillin/tazobactam MIC = 1 mg/L) prevented regrowth and suppressed emergence of resistance. [Extracted from the article]